Trial Profile
An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Talnetant (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors GSK